Logue Teresa C, Zullo Fabrizio, van Biema Fiamma, Son Moeun, London Lauren, Paranandi Sneha, Sciscione Anthony C, Rizzo Giuseppe, Mascio Daniele Di, Chauhan Suneet P
Department of Obstetrics and Gynecology, Christiana Care Health System, Newark, DE (Logue, Zullo, Roby, Paranandi, Sciscione, and Chauhan).
Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Rome, Italy (Zullo, Rizzo, and Di Mascio).
Am J Obstet Gynecol MFM. 2025 Feb;7(2):101604. doi: 10.1016/j.ajogmf.2025.101604. Epub 2025 Jan 7.
This study aimed to assess whether high- vs low-dose oxytocin regimens for labor augmentation are associated with differential risk of low Apgar score, neonatal acidosis, and other adverse labor outcomes.
We searched electronic databases (MEDLINE, Embase, the Cochrane Library, CINAHL, Scopus, ClinicalTrials.gov) from inception up to March 2024 using combinations of the following key words: "oxytocin," "oxytocin regimen," "oxytocin protocol," "oxytocin dosage," "active management," "high dose protocol," "low dose protocol," and "augmentation of labor."
We included quasi-randomized and randomized controlled trials comparing continuous oxytocin infusion with high-dose regimens (intervention group) vs low-dose regimens (control group) in nulliparous or multiparous patients undergoing labor augmentation. High-dose regimens were defined as a starting oxytocin dose of ≥4 mU/min, increasing in increments of 3 to 7 mU/min every 15 to 40 minutes. Low-dose regimens were defined as a starting oxytocin dose of <4 mU/min, increasing in increments of 1 to 2 mU/min every 15 to 40 minutes (PROSPERO CRD42024500197).
The coprimary outcomes were incidence of Apgar score <7 at 5 minutes and umbilical arterial pH <7.00. The secondary outcomes included cesarean delivery and chorioamnionitis. We performed random-effects head-to-head meta-analyses to compare high-dose with low-dose strategies, and reported summary risk ratios with 95% confidence intervals.
Ten randomized and quasi-randomized controlled trials of 5508 pregnancies met the inclusion criteria and were included in this meta-analysis. There was no difference in risk for the coprimary outcomes of Apgar score <7 at 5 minutes (relative risk, 0.94; 95% confidence interval, 0.60-1.46) and umbilical arterial pH <7.00 (relative risk, 0.77; 95% confidence interval, 0.50-1.20). There was also no difference in risk for cesarean delivery (relative risk, 0.83; 95% confidence interval, 0.67-1.02). High-dose oxytocin regimens were associated with significantly lower risk of chorioamnionitis (relative risk, 0.70; 95% confidence interval, 0.57-0.84; number needed to treat=25) and higher risk of tachysystole (relative risk, 1.32; 95% confidence interval, 1.21-1.43; P<.001).
When used for labor augmentation, high-dose oxytocin regimens decreased the risk of chorioamnionitis compared with low-dose regimens without affecting the risk of low Apgar scores, neonatal acidosis, or cesarean delivery. El resumen está disponible en Español al final del artículo.
本研究旨在评估高剂量与低剂量缩宫素方案用于引产时,与低Apgar评分、新生儿酸中毒及其他不良分娩结局的风险差异是否相关。
我们检索了电子数据库(MEDLINE、Embase、Cochrane图书馆、CINAHL、Scopus、ClinicalTrials.gov),从建库至2024年3月,使用以下关键词组合:“缩宫素”、“缩宫素方案”、“缩宫素协议”、“缩宫素剂量”、“积极管理”、“高剂量方案”、“低剂量方案”和“引产”。
我们纳入了在接受引产的初产妇或经产妇中,比较持续静脉滴注缩宫素的高剂量方案(干预组)与低剂量方案(对照组)的半随机和随机对照试验。高剂量方案定义为起始缩宫素剂量≥4 mU/分钟,每15至40分钟以3至7 mU/分钟的幅度增加。低剂量方案定义为起始缩宫素剂量<4 mU/分钟,每15至40分钟以1至2 mU/分钟的幅度增加(国际前瞻性注册系统注册号CRD42024500197)。
共同主要结局为5分钟时Apgar评分<7及脐动脉pH<7.00的发生率。次要结局包括剖宫产和绒毛膜羊膜炎。我们进行随机效应的直接比较荟萃分析,以比较高剂量与低剂量策略,并报告汇总风险比及95%置信区间。
10项涉及5508例妊娠的随机和半随机对照试验符合纳入标准并纳入本荟萃分析。5分钟时Apgar评分<7(相对风险,0.94;95%置信区间,0.60 - 1.46)及脐动脉pH<7.00(相对风险,0.77;95%置信区间,0.50 - 1.20)这两个共同主要结局的风险无差异。剖宫产风险也无差异(相对风险,0.83;95%置信区间,0.67 - 1.02)。高剂量缩宫素方案与绒毛膜羊膜炎风险显著降低相关(相对风险,0.70;95%置信区间,0.57 - 0.84;需治疗人数 = 25),与子宫收缩过速风险升高相关(相对风险,1.32;95%置信区间;1.21 - 1.43;P <.001)。
用于引产时,与低剂量方案相比,高剂量缩宫素方案可降低绒毛膜羊膜炎风险,且不影响低Apgar评分、新生儿酸中毒或剖宫产的风险。文章末尾提供西班牙语摘要。